about
A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery.Controlled release microspheres loaded with BMP7 suppress primary tumors from human glioblastomaThe performance of nanocarriers for transmucosal drug delivery.Nanoparticles as protein and gene carriers to mucosal surfaces.Nanoparticles for nasal vaccination.Chitosan-based drug nanocarriers: where do we stand?Polyarginine Nanocapsules as a Potential Oral Peptide Delivery Carrier.Biomaterials to suppress cancer stem cells and disrupt their tumoral niche.New scaffolds encapsulating TGF-β3/BMP-7 combinations driving strong chondrogenic differentiation.Implantable controlled release devices for BMP-7 delivery and suppression of glioblastoma initiating cells.PLGA:poloxamer blend micro- and nanoparticles as controlled release systems for synthetic proangiogenic factors.Polyaminoacid nanocapsules for drug delivery to the lymphatic system: Effect of the particle size.Optimization strategies for electrospun silk fibroin tissue engineering scaffolds.Pore size is a critical parameter for obtaining sustained protein release from electrochemically synthesized mesoporous silicon microparticles.A comparative study of chitosan and chitosan/cyclodextrin nanoparticles as potential carriers for the oral delivery of small peptides.A new potential nano-oncological therapy based on polyamino acid nanocapsules.Systemic heparin delivery by the pulmonary route using chitosan and glycol chitosan nanoparticles.Application of NMR spectroscopy to the characterization of PEG-stabilized lipid nanoparticles.Design and characterization of a new drug nanocarrier made from solid-liquid lipid mixtures.New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin.A new drug nanocarrier consisting of chitosan and hydoxypropylcyclodextrin.Polyglutamic acid-PEG nanocapsules as long circulating carriers for the delivery of docetaxel.The effect of hyaluronic acid on silk fibroin conformationProtein delivery based on uncoated and chitosan-coated mesoporous silicon microparticlesDocetaxel-loaded polyglutamic acid-PEG nanocapsules for the treatment of metastatic cancerProtection of the peptide glutathione by complex formation with alpha-cyclodextrin: NMR spectroscopic analysis and stability studyNanoparticles based on PLGA:poloxamer blends for the delivery of proangiogenic growth factorsNovel drug nanocarriers combining hydrophilic cyclodextrins and chitosanEnhanced in vivo therapeutic efficacy of plitidepsin-loaded nanocapsules decorated with a new poly-aminoacid-PEG derivativeNanocarriers & drug delivery: rational design and applicationsCo-delivery of RNAi and chemokine by polyarginine nanocapsules enables the modulation of myeloid-derived suppressor cellsIntracellular Delivery of an Antibody Targeting Gasdermin-B Reduces HER2 Breast Cancer AggressivenessSelf-assembled hyaluronan nanocapsules for the intracellular delivery of anticancer drugs
P50
Q33214432-9CA026EC-E173-4224-B1E5-D19222AB4388Q35793678-BF3CECE7-9D72-476B-B14F-DF97F31382DDQ36527739-283BC2FC-D148-417A-BAD9-5F1A11C04B16Q37331802-61A8F1D7-C149-4CED-A6BB-7083AFCD3BB6Q37361736-B54B33E9-2828-4140-98DE-7A543A2B0C06Q38000378-4F8784A8-D2C3-420F-90ED-9FAC4AB77220Q38730655-7F14CF9B-B7A4-4AD7-845C-003C659E90D5Q38784531-C4E6319E-E553-4FDB-AD0C-93BEC81AF887Q39021292-117AF9D3-E3FA-4692-9ED7-5B692DE3BBDEQ39035973-2FD5CD42-0A9A-4B1A-B700-7B2100B95440Q39651700-AF8A725C-AFE9-41CF-A1AA-8BC426A22146Q39745826-F0EB6D6D-E92E-4E6C-96E5-3FBFC5B9E910Q42026203-EBC13461-5859-4182-92B7-B59216D6E8AFQ42614014-8783A6C8-6034-4D74-ABD2-7F8EF960CA8EQ43183775-1379DC79-C141-4D8B-9C5C-217CC1254B00Q44120576-A5CD99AE-6DFB-4F4F-B1AF-15A8F50224D7Q44132617-B672EF36-E052-4AC6-A36F-CBFF577F511CQ45067177-FDD39683-327C-4BEA-AC62-3C35C03E6274Q46443372-43EC291A-2516-4584-9564-17371C372AB8Q46483406-E34AD426-4CF2-4C88-B804-8B2CBE2F0230Q46983335-4543FE52-C06D-4FB6-A7AE-F529140D8E98Q55461180-B7DAAE7A-C771-4199-AD24-FCC9E736E6F0Q57219860-AEA24701-74CA-4194-9AD5-F17687D67676Q58810757-522B9437-6D55-4AC9-A897-F80C7539614AQ59342609-F4EF1931-CED0-4C39-BE9F-6EF22C6E53BFQ79947894-F170A00D-484D-4F6C-B7D6-AC1D59878146Q84646202-4069BAD4-F867-4CB5-89B8-5F3F55C68AF3Q84722163-A09B07C0-2C12-4A8F-A458-1B377B6C16AAQ86730243-80425EF3-AB65-4B89-B61C-9EECBE069579Q87547386-EA8D6D3D-3B80-4ABB-8B5A-A74C642089CBQ90799323-FEF0AC56-02F7-4398-8E94-7DE9991EF514Q91831518-7125CC16-1C3B-4523-8624-0089B9C16C4EQ92534872-832FB8E1-1BCA-4F1C-9FC7-754CB012C86C
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marcos Garcia-Fuentes
@ast
Marcos Garcia-Fuentes
@en
Marcos Garcia-Fuentes
@es
Marcos Garcia-Fuentes
@nl
type
label
Marcos Garcia-Fuentes
@ast
Marcos Garcia-Fuentes
@en
Marcos Garcia-Fuentes
@es
Marcos Garcia-Fuentes
@nl
prefLabel
Marcos Garcia-Fuentes
@ast
Marcos Garcia-Fuentes
@en
Marcos Garcia-Fuentes
@es
Marcos Garcia-Fuentes
@nl
P106
P1153
8577775700
P21
P31
P496
0000-0002-6393-6469